RE:RE:MSD Merck on the lookout for new opportunities within immunoMarch 21, 2024 - Pembrolizumab/Olaparib (Lynparza) Misses Survival End Points in NSCLC Subgroup
https://www.targetedonc.com/view/pembrolizumab-olaparib-misses-survival-end-points-in-nsclc-subgroup